Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
101.68
+4.59 (4.73%)
Mar 19, 2026, 4:00 PM EDT - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $106.67, which forecasts a 4.91% increase in the stock price over the next year. The lowest target is $82 and the highest is $125.
Price Target: $106.67 (+4.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $107 → $110 | Buy | Maintains | $107 → $110 | +8.18% | Mar 19, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $106 | Buy | Maintains | $95 → $106 | +4.25% | Mar 19, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $115 → $125 | Strong Buy | Maintains | $115 → $125 | +22.93% | Mar 19, 2026 |
| Barclays | Barclays | Buy Maintains $113 → $119 | Buy | Maintains | $113 → $119 | +17.03% | Mar 19, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $65 → $95 | Hold | Maintains | $65 → $95 | -6.57% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
445.37M
from 46.02M
Increased by 867.86%
Revenue Next Year
176.01M
from 445.37M
Decreased by -60.48%
EPS This Year
1.89
from -2.05
EPS Next Year
-0.67
from 1.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 641.6M | 461.0M | |||
| Avg | 445.4M | 176.0M | |||
| Low | 19.6M | 13.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1,294.2% | 3.5% | |||
| Avg | 867.9% | -60.5% | |||
| Low | -57.4% | -97.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.04 | 2.51 | |||
| Avg | 1.89 | -0.67 | |||
| Low | -2.31 | -2.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 33.2% | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.